FDA researchers report Novo Nordisk's clotting drug NovoSeven has been linked to deaths, strokes, heart attacks and other complications, mostly when used for off-label treatments. The drug, introduced in 1999 to treat hemophiliacs, has shown potential for treating cerebral hemorrhages, but the FDA scientists called for rigorous safety studies of new uses for the drug.

Related Summaries